Rx-360 Announces the Release of the Rx-360 Supplier Assessment Questionnaire
Rx-360 has announced the release of the Rx-360 Supplier Assessment Questionnaire (SAQ). The SAQ was prepared by the Rx-360 Supplier-Led Working Group, an Rx-360 working group consisting of members from both pharmaceutical companies and leading suppliers to the pharmaceutical industry. Through this Working Group, members can share perspectives and work collaboratively to achieve greater harmonisation and efficiencies in the supply chain to better serve patients.
Pharmaceutical manufacturers and industry suppliers recognise the inefficiency and waste of resources when each individual pharmaceutical company creates its own supplier assessment questionnaire. Suppliers routinely exhaust valuable resources continuously completing slightly different forms of substantially similar questionnaires. To create the current Supplier Assessment Questionnaire, the Working Group analysed numerous sample questionnaires submitted by Rx-360 members. In addition to standardised content, document formatting and question completion was optimised for accuracy and ease of completion by suppliers.
The Rx-360 SAQ covers standard information that would be included in most supplier assessment questionnaires. The 4-part questionnaire is more detailed than most, but will decrease the number of times that questionnaires will need to be filled out by the supplier, while significantly decreasing the turn-around time back to manufacturers. The SAQ consists of four (4) modules:
• General Company Information
• Specific Site Information
• Product Supplier Appendix
• Services Supplier Appendix.
The Working Group believes the Rx-360 SAQ will create helpful efficiencies for both suppliers and pharmaceutical manufactures alike by
• Eliminating time-consuming redundancies
• Streamlining the process of approving suppliers
• Allowing comparative analysis of basic information.
The Supplier Led Working Group strongly encourages suppliers and manufacturers to consider adopting this SAQ in standard use. All modules will be available shortly for public download at the Rx-360 website.
The Supplier Led Working Group will be holding a public webinar to introduce the documents on 28 August 2014.
Anyone interested in learning more or considering use of the questionnaires is encouraged to attend. To RSVP, please register through this link: www4.gotomeeting.com/register/163722479.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance